

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV970405007US, on the date shown below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: 5/6/09 Signature: Andrea Borden
(Andrea Borden)

Docket No.: ALXN-P01-095
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Figdor et al.

Application No.: 10/524,394

Confirmation No.: 6059

Filed: December 12, 2005

Art Unit: 1646

For: METHODS OF IDENTIFYING AND
ISOLATING CELLS EXPRESSING DC-SIGN

Examiner: R. Li

STATEMENT FOR BIOLOGICAL DEPOSITS UNDER 37 C.F.R. 1.801-1.809

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The specification of the United States Patent Application No. 10/524,394 refers to monoclonal antibodies AZN-D1 and AZN-D2. Hybridomas that produce monoclonal antibodies AZN-D1 and AZN-D2 were deposited on April 8, 1999 with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton Down, Salisbury, SP4 0JG, UK, under ECACC accession numbers 99040818 and 99040819, respectively.


The deposit has been made under the terms of the Budapest Treaty by the Applicants.

Access to the deposits will be available during pendency of Application No. 10/524,394 to one determined by the Director to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. § 122.

Subject to 37 C.F.R. 1.808(b), all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent.

Dated: May 6, 2009

Respectfully submitted,

By 

Tianxin (Cynthia) Chen, Ph.D., J.D.

Registration No.: 61,193

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant